# Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma

> **NCT03084640** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** CMP-001
- **DRUG:** Pembrolizumab
- **DRUG:** CMP-001

## Key facts

- **NCT ID:** NCT03084640
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-04
- **Primary completion:** 2021-07-02
- **Final completion:** 2021-09-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03084640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03084640, "Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03084640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*